Catastrophic antiphospholipid syndrome - 20 years later

Current Rheumatology Reviews

Volumn 9, Issue 2, 2013, Pages 73-80

  Rodríguez Pintó, Ignasi ^a   Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

ACUTE PHASE PROTEIN; ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEFIBROTIDE; ECULIZUMAB; FIBRINOLYTIC AGENT; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROSTACYCLIN; RITUXIMAB;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLOOD VESSEL OCCLUSION; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL CLASSIFICATION; CLINICAL FEATURE; CONSENSUS; DEEP VEIN THROMBOSIS; DENGUE; DISEASE PREDISPOSITION; DISEASE REGISTRY; DISSEMINATED INTRAVASCULAR CLOTTING; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTOSIS; LUNG EDEMA; MALARIA; MICROTHROMBUS; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; STOMACH ULCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINARY TRACT INFECTION;

EID: 84882806150     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/15733971113099990003     Document Type: Article

References (46)

1. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19(4): 508-12.
2. Piette J-C, Cervera R, Levy RA, et al. The catastrophic antiphospholipid syndrome--asherson's syndrome. Ann de Méd Interne 2003; 154(4): 195-6.
3. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome. clinical and laboratory features of 50 patients. Medicine 1998; 77(3): 195-207.
4. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 2001; 80(6): 355-77.
5. Bucciarelli S, Cervera R, Espinosa G, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev 2006; 6(2): 72-5.
6. Cervera R, Piette J-C, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46(4): 1019-27.
7. Asherson R, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12(7): 530-4.
8. Cervera R, Font J, Gómez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64(8): 1205-9.
9. Cervera R, Tektonidou MG, Espinosa G, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 2011; 20(2): 165-73.
10. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10(2): 74-9.
11. Cervera R, Tincani A. European working party on systemic lupus erythematosus and european forum on antiphospholipid antibodies: two networks promoting european research on autoimmunity. Lupus 2009; 18(10): 863-8.
12. Asherson RA, Pierangeli SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis 2007; 66(4): 429-32.
13. Asherson RA, Pierangeli S, Cervera R. Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol 2007; 34(9): 1793-5.
14. Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes (MAPS): semantic or antisemantic? Autoimmun Rev 2008; 7(3): 164-7.
15. Asherson RA, Cervera R, Font J. Multiorgan thrombotic disorders in systemic lupus erythematosus: a common link? Lupus 1992; 1: 199-203.
16. Cervera R, Bucciarelli S, Plasín MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the CAPS Registry. J Autoimmun 2009; 32(3-4): 240-5.
17. Espinosa G, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome and sepsis. a common link? J Rheumatol 2007; 34(5): 923-6.
18. Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54(8): 2568-76.
19. Asherson RA, Espinosa G, Cervera R, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 2005; 64(6): 943-6.
20. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63(6): 730-6.
21. Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10(11): 664-8.
22. Asherson R A, Espinosa G, Menahem S, et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Aarthritis Rheum 2008; 37(6): 366-72.
23. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum 2013; 42(4): 417-23.
24. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10(11): 1222-6.
25. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa b: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24(11): 1131-8.
26. Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 2005; 33(1): 11-7.
27. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003; 48(12): 3320-7.
28. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29(3): 173-84.
29. Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007; 34(2): 346-52.
30. Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008; 17(1): 50-5.
31. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48(11): 3272-9.
32. López-Pedrera C, Ruiz-Limón P, Aguirre MÁ, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011; 70(4): 675-82.
33. Espinosa G, Cervera R. Recent trends in the management of antiphospholipid syndrome (hughes syndrome). Drugs of today (Barc) 2010; 46(1): 39-47.
34. Ketari Jamoussi S, Zaghdoudi I, Ben Dhaou B, et al. [catastrophic antiphospholipid syndrome and rituximab: a new report]. Tunis Med 2009; 87(10): 699-702.
35. Nageswara Rao AA, Arteaga GM, Reed AM, Gloor JM, Rodriguez V. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 2009; 52(4): 536-8.
36. van Wissen S, Bastiaansen BA, Stroobants AK, et al. Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour-a case report. Lupus 2008; 17(6): 586-90.
37. Manner H, Jung B, Tonassi L, et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (caps) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008; 335(5): 394-7.
38. Haque W, Kadikoy H, Pacha O, et al. Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy. Rheumatol Int 2010; 30(6): 719-23.
39. Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, LirolaCruz J, Neth O. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics 2010; 125(6): e1523-8.
40. Rubenstein E, Arkfeld DG, Metyas S, et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006; 33(2): 355-7.
41. Morabito F, Gentile M, Gay F, et al. Insights into defibrotide: an updated review. Expert Opin Biol Ther 2009; 9(6): 763-72.
42. Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 2002; 29(9): 2006-11.
43. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355(12): 1233-43.
44. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362(18): 1744-5.
45. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein c5 for salvage treatment of severe antibodymediated rejection. Am J Transplant 2009; 9(1): 231-5.
46. Erkan D, Asherson RA, Espinosa G, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62(6): 530-3.